Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1269

Shown on this page

Current sort

Stored official records

Conditions: Ventricular Tachycardia (VT)
Interventions: Sphere-9 Catheter with the Affera Mapping and Ablation System; Device
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Cleveland, Ohio + 3 more

Conditions: Neuroblastoma
Interventions: Naxitamab, Tipifarnib; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: 1 Year to 21 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 12
States / cities: Little Rock, Arkansas • Hartford, Connecticut • Miami, Florida + 9 more

Conditions: Endometrial Cancer, Platinum-resistant Ovarian Cancer, Testicular Cancer
Interventions: CTIM-76; Drug
Lead sponsor: Context Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Little Rock, Arkansas • Beverly Hills, California • Denver, Colorado + 11 more

Conditions: Atypical Teratoid/Rhabdoid Tumor, DIPG Brain Tumor, Diffuse Intrinsic Pontine Glioma, Embryonal Tumor With Multilayered Rosettes, Ewing Sarcoma, Neuroblastoma, Osteosarcoma
Interventions: AMXT 1501 Dicaprate, Eflornithine (DFMO); Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Up to 26 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 14
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 11 more

Conditions: Metastatic Colorectal Cancer
Interventions: Bevacizumab-awwb, FOLFIRI Regimen, Panitumumab, Sotorasib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 26
States / cities: Chandler, Arizona • Fullerton, California • Long Beach, California + 21 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Not listed
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 31
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Neuroblastoma
Interventions: Difluoromethylornithine (DFMO); Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: 1 Year to 30 Years
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2033
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 38 more

Conditions: Pulmonary Arterial Hypertension
Interventions: IKT-001, Placebo; Drug
Lead sponsor: Inhibikase Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Scottsdale, Arizona • Beverly Hills, California • Santa Barbara, California + 12 more

Conditions: Non Small Cell Lung Cancer
Interventions: Cetrelimab, tolododekin alfa; Drug
Lead sponsor: Ankyra Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Coral Gables, Florida • Jacksonville, Florida • Peoria, Illinois + 8 more

Conditions: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, MRI, Pembrolizumab, Questionnaire Administration, Tivozanib; Procedure · Biological · Other + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 425
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 339 more

Conditions: Stroke, Stroke, Acute, Stroke, Ischemic
Interventions: Endovascular Stroke Treatment, Medical Management; Procedure · Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Abrocitinib 200 MG Oral Tablet, Placebo, Ritlecitinib; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 35 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Orange, California • Palo Alto, California • San Francisco, California + 20 more

About this Vanderbilt University Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Vanderbilt University Medical Center

Filter and sort this campus

Stored official records

Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

Neuroblastoma Maintenance Therapy Trial

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Treatment With Endovascular Intervention for STroke Patients With Existing Disability

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

About this Vanderbilt University Medical Center institution page